Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

Completed · Phase 2

Conditions studied: Melanoma (Skin)

In brief

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood. Combining vaccine therapy with sargramostim may cause a stronger immune response and kill more tumor cells. PURPOSE: This randomized phase II trial is studying vaccine therapy and sargramostim to see how well they work compared to vaccine therapy alone in treating patients with stage II B, stage IIC, stage III, or stage IV melanoma.

Key facts

Study ID

NCT00089193

Run by

Craig L Slingluff, Jr

Starts

2003-09-01

Last updated by the study team

2014-12-23

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Washington Cancer Institute at Washington Hospital Center — Washington D.C., District of Columbia, United States
• Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States
• Hillman Cancer Center at University of Pittsburgh Cancer Institute — Pittsburgh, Pennsylvania, United States
• MD Anderson Cancer Center at University of Texas — Houston, Texas, United States
• Cancer Center at the University of Virginia — Charlottesville, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.